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EDITORIAL
Minimal experimental requirements for definition of
extracellular vesicles and their functions: a position
statement from the International Society for Extracellular
Vesicles
Secreted membrane-enclosed vesicles, collectively called extracellular vesicles (EVs), which include exosomes,
ectosomes, microvesicles, microparticles, apoptotic bodies and other EV subsets, encompass a very rapidly
growing scientific field in biology and medicine. Importantly, it is currently technically challenging to obtain a
totally pure EV fraction free from non-vesicular components for functional studies, and therefore there is a
need to establish guidelines for analyses of these vesicles and reporting of scientific studies on EV biology.
Here, the International Society for Extracellular Vesicles (ISEV) provides researchers with a minimal set of
biochemical, biophysical and functional standards that should be used to attribute any specific biological
cargo or functions to EVs.
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O
ver the past decade, there has been a rapid growth
in studies of secreted membrane vesicles, collec-
tively called extracellular vesicles (EVs). Publica-
tions in high-impact journals have proposed exciting
functional roles of EVs. In particular, the knowledge
that EVs can shuttle functional nucleic acids between cells
(mRNA, miRNA or other RNA species) has fundamen-
tally changed the thinking about gene regulation, as the
EVs can regulate the recipient cell at a post-transcriptional
level (13).
However, the extracellular milieu is more complex
as several body fluids (especially serum/plasma) harbour
extracellular RNA (exRNA) in other non-EV carriers,
including protein complexes (AGO2) (4) and lipoproteins
[HDL and LDL (5)]. Separation of these non-vesicular
entities from EV is not fully achieved by common EV
isolation protocols, including centrifugation protocols or
commercial kits that claim EV or ‘‘exosome’’ isolation/
purification. Also, the composition of recovered EVs vary
vastly according to the protocols used (68). In parti-
cular, polymer-based methods to precipitate EVs (used by
some commercial kits) do not exclusively isolate EVs,
and are likely to co-isolate other molecules, including
RNAprotein complexes. Consequently, there is a need to
determine the distinct contribution of EVs in any experi-
ment that describes the molecular content or the func-
tional consequences of the isolated material.
We recognize that different experimental systems,
sources of biological specimens, investigator’s experience
and instrumentation used contribute to the heterogeneity
of published protocols and the interpretation of results.
A framework for providing data and attributing func-
tions to EVs was discussed by the Executive Committee
of the International Society for Extracellular Vesicles
(ISEV), a group of scientists with collective long-term
expertise in the field of EV biology. Here, we propose
a series of criteria, based on current best-practice, that
represent the minimal characterization of EVs that
should be reported by investigators. Adoption of these
criteria should aid researchers in planning studies as well
as reporting their results. In addition, we suggest appro-
priate controls that should be included in EV-related
functional studies. These controls should support con-
clusions regarding the functions of EVs and their
relationship to physiologic and pathologic mechanisms.
The term ‘‘exosomes’’ is the most commonly used word
to designate any type of EV (Fig. 1), and this has become
a ‘‘buzz term’’ for EV-related science. The actual meaning
of this word, however, is not universally accepted [see letter
by Gould and Raposo (9)]. Many publications specify that
exosomes are formed in endosomal multivesicular com-
partments and are secreted when these compartments
fuse with the plasma membrane. However, the isolated
material generally studied contains a mixture of EVs.
Unfortunately, the field of EV research has not matured
to the point that we can propose a list of EV-specific
‘‘markers’’ that distinguish subsets of EVs from each other,
for example, EVs produced via budding from the cell
membrane or produced via endosomal compartments.
The criteria we provide here can be used by researchers
to guide them in discriminating EV from non-EV compo-
nents. These criteria will be updated with improvements
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in the ‘‘state of the art,’’ and we hope to eventually be able
to provide specific markers and characteristics of EV sub-
types. In the meantime, readers can also refer to 2 detailed
Position Papers of ISEV published in 2013, listing recom-
mendations on EV isolation (10) and EV/exRNA analysis
(11).
Minimal requirements to claim the presence of
EVs in isolates
One of the first criteria to define EVs is that they are
isolated from extracellular fluids, that is, from condi-
tioned cell culture medium or body fluids. Importantly,
collection of the EV-containing fluid must be gentle,
limiting cell disruption. Mechanical disruption of cells
or tissues can result in isolation of vesicles that originate
from the intracellular compartments, which obviously
would reduce the purity of EVs. Therefore, the term
‘‘EVs’’ may not be appropriate for materials isolated in
such ways.
Since there is currently no consensus on a ‘‘gold-
standard’’ method to isolate and/or purify EVs, it cannot
be claimed that there is an ‘‘optimal’’ method that should
be uniformly used. The reader should be aware that the
methods that are most efficient probably depend on (a) the
specific scientific question asked and (b) on the down-
stream applications used. However, we urge researchers to
describe in detail the methods used for EV isolation, to
allow interpretation and replication by other researchers.
Further, we also suggest a format of characteristics of EVs
that should be analyzed and then provided in publication.
General characterization of EVs
A general overview of the protein composition of each
EV preparation should be provided, at least in a first
publication, including description or quantitation of
components not necessarily expected to be present on
or in EVs (see Table I). Although numerous proteomic
analyses have highlighted proteins commonly found
in exosome preparations, it is becoming clear that these
do not represent ‘‘exosome-specific’’ markers but rather
‘‘exosome-enriched’’ proteins, as different subsets of
secreted EVs contain many common markers. However,
the relative proportions of different proteins seem to vary
in the different types of EVs. Therefore, we suggest
that investigators report the amount of several proteins
(3 or more) in at least a semi-quantitative manner in any
EV preparation, including EV isolates from body fluids
or obtained from secreting cells in vitro. The proteins
described and characterized should be proteins expected
to be present in the EVs of interest, especially transmem-
brane proteins and cytosolic proteins with membrane-
binding capacity (Table I, groups 1 and 2). In addition, the
level of presence of proteins not expected to be enriched
in EVs of endosomal origin should also be determined
(Table I, group 3). This description will cast light on the
extent of co-isolation of EVs of different intracellular
origins and nature in the isolates (Table I). Furthermore,
investigators can compare their protein isolates with those
described in other EVs, by searches within databases
[EVpedia and Vesiclepedia (12,13)].
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Fig. 1. Comparative evolution of the use of different terms for EVs in the literature. An advanced search was performed in PubMed at
the end of December 2013 to find, for each year of publication, all articles using the given term (singular or plural) as text word:
exosome(s), microvesicles, oncosome(s), ectosome(s), prostasome(s), matrix/calcifying vesicle(s). Year of final publication (and not
advanced online date) of articles in English (and not other languages) was taken into account. Manual elimination of articles describing
non-EV-related work was performed for exosome(s) (RNA-excision machinery) and microvesicle(s) (intracellular secretory vesicles).
Use of the term microparticle(s) could not be reliably evaluated, since it is massively used to refer to non-vesicle-related particles.
Notably, from 2004 onwards, the term ‘‘exosome’’ has become the most often used in published articles describing EVs, whereas the
term ‘‘extracellular vesicles,’’ chosen as generic term at creation of ISEV in September 2011, is steadily growing. This figure is not
intended to show expansion of the EV field as compared to other fields, since numbers are not normalized to the total number of
scientific medico-biological publications per year.
Jan Lo¨tvall et al.
2
(page number not for citation purpose)
Citation: Journal of Extracellular Vesicles 2014, 3: 26913 - http://dx.doi.org/10.3402/jev.v3.26913
Analytic approaches can include Western blots (WB),
(high resolution) flow cytometry (FACS) or global pro-
teomic analysis using mass spectrometry techniques to
identify e.g. transmembrane proteins. We recommend that
analyses should be performed in a semi-quantitative
manner, for example, using intensity analysis of Western
blot signals or specific mean fluorescence intensity as
compared to isotype control in FACS. When EVs secreted
in vitro by cultured cells are analyzed, their composition
should ideally be compared with that of the secreting cells,
to determine level of enrichment of the EV components.
This is not possible for biological fluid-derived EVs, as these
are produced by a vast array of cells in the tissues. In that
case, we recommend that reports include the relative
proportion of different EV-associated proteins.
Table I lists the different categories and examples of
proteins whose presence/absence should be simultaneously
analyzed. Caution should be taken when using the enzy-
matic activity of proteins to indirectly determine the
concentration of vesicles in any sample. An example
of this is acetylcholinesterase (ACHE), a GPI-anchored
protein localized in the membrane of reticulocytes, which
is present in multiple membrane-anchored and non-
membrane-anchored secreted forms also in other cells
(14). While the activity of ACHE has been used as a marker
of EVs released by reticulocytes, the use of this (or any
other proteins in which activity can be measured) requires
confirmation of the presence of the protein by Western
blotting or functional inhibition by a specific enzyme
inhibitor, as well as the recognition that these do not
represent specific markers of EVs or exosomes (Table I,
group 4). Therefore, their use should be restricted to cases
where it is not possible to use other quantitative measures
as described above, and the reasons for using them should
be clearly justified.
Given the variable quality of commercial and home-
made antibodies used for quantitation studies, appropri-
ate negative controls should also be used and their results
should be presented. These controls are best provided
in the first reports using these antibodies. Ideally, the
signal obtained in EVs should be compared to signals
obtained from the biological fluid or conditioned medium
depleted of EVs (i.e. recovered after the isolation proce-
dure) and/or from complete medium non-conditioned
by cells but processed for EV purification as conditioned
medium. The reader should be aware that the superna-
tant, for example, after a 70-minute post-ultracentrifugation,
still contains significant quantities of remaining EVs
(15). The Methods section of reports should also con-
tain details of the antibodies used (source, catalogue
number and dilution) and conditions of preparations
of the samples (e.g. reducing/non-reducing conditions
for Western blot, an important issue to analyze some
tetraspanins).
Characterization of single vesicles
We recommend characterization of single vesicles within
a mixture to be performed, to provide an indication of the
heterogeneity of the EV preparation studied. As a general
rule, at least 2 different technologies should be used to
characterize individual EVs. For electron microscopy
Table I. Different categories of proteins and their expected presence in EV isolates, including some examples (non-exclusive)
1. Transmembrane or lipid-bound
extracellular proteins 2. Cytosolic proteins 3. Intracellular proteins 4. Extracellular proteins
Argues presence of a membrane
in the isolate
With membrane- or
receptor-binding capacity
Associated with compartments
other than plasma membrane or
endosomes
Binding specifically or
non-specifically to membranes,
co-isolating with EVs
Present or enriched in EVs/
exosomes
Present or enriched in EVs/
exosomes
Absent or under-represented in
EVs/exosomes, but present in
other types of EVs
Variable association with EVs
Examples:
Tetraspanins (CD9, CD63,
CD81)
Integrins (ITG**) or cell
adhesion molecules (CAM*)
Growth factor receptors
Heterotrimeric G proteins
(GNA**)
Phosphatidylserine-binding
MFGE8/lactadherin
Examples:
Endosome or membrane-
binding proteins (TSG101,
annexinsANXA*,
RabsRAB*)
Signal transduction or
scaffolding proteins
(syntenin)
Examples:
Endoplasmic reticulum
(Grp94HSP90B1,
calnexinCANX)
Golgi (GM130)
Mitochondria (cytochrome
CCYC1)
Nucleus (histonesHIST*H*)
Argonaute/RISC complex
(AGO*)
Examples:
Acetylcholinesterase (ACHE)
Serum albumin
Extracellular matrix
(fibronectinFN1,
collagenCOL*A*)
Soluble secreted proteins
(cytokines, growth factors,
matrix metalloproteinases
MMP*)
At least one protein of each category 1, 2 and 3 should be quantified in the EV preparations. EV association of proteins of category
4 should be demonstrated by other means.
Italics: official gene names; *, ** denotes different possible family members.
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(Transmission EM) or atomic force microscopy (AFM),
images should show a wide field encompassing multiple
vesicles in addition to close-up images of single vesicles.
For larger vesicles such as apoptotic bodies, cytospins
and/or immunofluorescent images may be presented
to provide an overview of vesicles isolated, again not
focusing on a single vesicle. Size distribution measure-
ments of EVs, such as nanoparticle-tracking analysis,
dynamic light scattering, or resistive pulse sensing pro-
vide diameters of a large number of vesicles. However, the
values acquired with these techniques should be com-
pared with TEM, AFM or other microscopy techniques,
since they do not distinguish membrane vesicles from co-
isolated non-membranous particles of similar size.
Studies of the functional activity of EVs:
recommendations for controls
When in vitro functional studies are performed with
isolated EVs, a quantitative analysis of the dosefunction
relationship should be presented. This doseresponse
curve should be supplemented by data on the volume of
starting fluid and/or the number of producing cells used
to isolate the range of functional EVs.
It is important to make use of systematic negative
controls which should exhibit minimal functional effects.
These may include ‘‘mock’’ EVs obtained from culture
medium that has not been conditioned by the cells of
interest (but incubated at 378C as if used in culture) or
the fluid remaining after the EV isolation (for body fluids
and conditioned medium). These controls provide in-
sights into the ‘‘background’’ functional activity or signal
and possibly the proportion of functional ‘‘activity’’
present in the soluble versus EV-associated components
of the isolated fluid. Clearly, there is value to negative
controls being performed at concentrations of negative
EVs approximating those of functional EVs. Foetal calf
serum EVs and their protein and RNA cargo can
influence measurements (16,17). Thus, there should be
efforts to perform studies in the absence of the serum-
derived EVs. In this regard, it should be noted that
70 minutes of high speed centrifugation is insufficient
to remove EV RNA cargo in foetal calf serum (18).
The ISEV Executive Committee remains concerned
about the future reporting of functional changes ascribed
to specific single or small clusters of molecules (protein,
RNA or other) associated with EVs. This will increasingly
be important, as EV biomarkers, EV therapeutics and
fundamental mechanisms of EV function are brought
to clinical utility or claimed in patent protection drafts.
Demonstration of association of these molecules to EVs
should therefore be provided for such use. Some proteins
(Table I, group 4), but also different RNA species (5),
have been variably described as co-isolated with EVs, but
may not necessarily be harboured in EVs. For instance,
MMP9 has been described as secreted with EVs (19,20) or,
conversely, as a soluble non-EV-associated molecules (21).
A direct approach to prove association of these mole-
cules to EVs can be fractionation of the EV preparation
using density gradients. Separation of EVs from other
particulate material can be guaranteed only by floatation
(upward displacement). However, for some other se-
parations, sedimentation (downward displacement)
may be more appropriate. Such separation should be
followed by qPCR or other biochemical detection meth-
ods, and the functional moiety and/or biomarker cluster
should be co-fractionated with the transmembrane or EV-
enriched cytosolic protein used to characterize EVs (Table I).
Thus, the functional activity should be resident within
defined density gradient fractions specifically containing
the EV proteins. Importantly, we are aware that some den-
sity gradients often used may alter or impede functional
tests performed.
An alternative approach to link functional activity, or
specific molecules, with isolated EVs may be based upon
antibody-mediated capture or depletion of EVs from
the biofluid or conditioned medium. The antibodies used
should be specific to the transmembrane protein of the
characterized EVs. In these studies, depleted preparations
will have lost functional activity, whereas the antibody-
captured EVs should retain it (if proper and non-
destructive elution from the antibody-coated beads used
for capture is technically possible). We realize that EVs
with functional activity but without the transmembrane
protein also exist, and thus would not be depleted nor
captured with this approach.
Another approach would include the use of fluores-
cent labels of EVs incubated with target cells. Unstained
EVs and non-EV dye materials and aggregates must be
eliminated with appropriate technology when this method
is used. As EVs elicit their function by binding to, fusing
with or being uptaken into recipient cells, it could be
possible to determine a functional activity in fluorescent
cells (EV-associated cells) versus non-fluorescent cells.
In the absence of any of the above proposed controls,
investigators may still conclude that an extracellular
functional activity exists and affects recipient cells, but
the specific EV nature of this function should not be
claimed.
Conclusion
The EV field is rapidly expanding and becoming in-
creasingly complex, especially as it overlaps with the even
newer field of exRNA-mediated communication. A gen-
eric biological standard of EVs, or of ‘‘exosomes,’’ would
be very useful as a baseline to compare EV preparations
obtained by individual laboratories, and we are aware that
European and US networks of researchers are working
towards establishing such standards. When available, these
standards may provide comparative EV preparative data
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and also could support inter-laboratory comparisons.
However, such standards are not yet available, due to the
lack of universal or unequivocally specific markers of EVs,
a situation linked to the fact that the content of EVs is
probably highly context-dependent. Such tools will there-
fore only become available with increased knowledge of
the core composition and, perhaps, core functions of EVs
recovered from diverse sources. Nonetheless, to harmonize
research practice in the field of EV research, and to ensure
an acceptable level of data comparability, we herein
propose that technical and experimental information is
provided in significant detail in any published scientific
article, and that the characterization includes a minimal
set of proofs of the EV relationship to the observations
reported. We hope that the minimal requirements pre-
sented in this editorial therefore will increase awareness
of all researchers for potential confounders in their EV-
related results, and thus help editors and reviewers of
journals other than J Extracell Vesicles, less specialized
in EVs, to better assess and promote advances in the
exceptionally promising field of EV research.
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